CONTEXT: Endogenous estradiol, testosterone, and SHBG may influence the risk of hip fracture. DESIGN AND METHODS: From the Women's Health Initiative Observational Study, 39,793 eligible postmenopausal women did not have a previous hip fracture and were not using estrogen or other bone-active therapies. Of these, 400 who had a first-time nonpathological hip fracture (median follow-up, 7 yr) were matched to 400 controls by age, ethnicity, and baseline blood draw date. Estradiol, testosterone, and SHBG were measured in banked baseline serum. RESULTS: Compared with women in the lowest tertiles, those with bioavailable testosterone in the highest tertile had a lower risk [odds ratio (OR) = 0.62; 95% confidence interval (CI) = 0.44-0.88]; those with bioavailable estradiol in the highest tertile had a lower risk (OR = 0.44; 95% CI = 0.29-0.66), and those with SHBG in the highest tertile had a higher risk (OR = 1.90; 95% CI = 1.31-2.74) of hip fracture. In models with all three hormones and potential confounders, high SHBG remained a strong independent risk factor (OR = 1.76; 95% CI = 1.12-2.78), high bioavailable testosterone remained protective (OR = 0.64; 95% CI = 0.40-1.00), but estradiol no longer was associated (OR = 0.72; 95% CI = 0.42-1.23). CONCLUSIONS: High serum SHBG is associated with an increased risk of subsequent hip fracture and high endogenous testosterone with a decreased risk, independent of each other, serum estradiol concentration, and other putative risk factors. But endogenous estradiol has no independent association with hip fracture.
CONTEXT: Endogenous estradiol, testosterone, and SHBG may influence the risk of hip fracture. DESIGN AND METHODS: From the Women's Health Initiative Observational Study, 39,793 eligible postmenopausal women did not have a previous hip fracture and were not using estrogen or other bone-active therapies. Of these, 400 who had a first-time nonpathological hip fracture (median follow-up, 7 yr) were matched to 400 controls by age, ethnicity, and baseline blood draw date. Estradiol, testosterone, and SHBG were measured in banked baseline serum. RESULTS: Compared with women in the lowest tertiles, those with bioavailable testosterone in the highest tertile had a lower risk [odds ratio (OR) = 0.62; 95% confidence interval (CI) = 0.44-0.88]; those with bioavailable estradiol in the highest tertile had a lower risk (OR = 0.44; 95% CI = 0.29-0.66), and those with SHBG in the highest tertile had a higher risk (OR = 1.90; 95% CI = 1.31-2.74) of hip fracture. In models with all three hormones and potential confounders, high SHBG remained a strong independent risk factor (OR = 1.76; 95% CI = 1.12-2.78), high bioavailable testosterone remained protective (OR = 0.64; 95% CI = 0.40-1.00), but estradiol no longer was associated (OR = 0.72; 95% CI = 0.42-1.23). CONCLUSIONS: High serum SHBG is associated with an increased risk of subsequent hip fracture and high endogenous testosterone with a decreased risk, independent of each other, serum estradiol concentration, and other putative risk factors. But endogenous estradiol has no independent association with hip fracture.
Authors: Jennifer S Lee; Bruce Ettinger; Frank Z Stanczyk; Eric Vittinghoff; Vladimir Hanes; Jane A Cauley; Walt Chandler; Jim Settlage; Mary S Beattie; Elizabeth Folkerd; Mitch Dowsett; Deborah Grady; Steven R Cummings Journal: J Clin Endocrinol Metab Date: 2006-08-01 Impact factor: 5.958
Authors: A L Eriksson; M Lorentzon; D Mellström; L Vandenput; C Swanson; N Andersson; G L Hammond; J Jakobsson; A Rane; E S Orwoll; O Ljunggren; O Johnell; F Labrie; S H Windahl; C Ohlsson Journal: J Clin Endocrinol Metab Date: 2006-08-22 Impact factor: 5.958
Authors: Natalia O Kuchuk; Natasja M van Schoor; Saskia M F Pluijm; Johannes H Smit; Willem de Ronde; Paul Lips Journal: Clin Endocrinol (Oxf) Date: 2007-06-06 Impact factor: 3.478
Authors: Chevon M Rariy; Sarah J Ratcliffe; Rachel Weinstein; Shalender Bhasin; Marc R Blackman; Jane A Cauley; John Robbins; Joseph M Zmuda; Tamara B Harris; Anne R Cappola Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958
Authors: A D Coviello; W V Zhuang; K L Lunetta; S Bhasin; J Ulloor; A Zhang; D Karasik; D P Kiel; R S Vasan; J M Murabito Journal: J Clin Endocrinol Metab Date: 2011-07-13 Impact factor: 5.958
Authors: Vanessa W Lim; Jun Li; Yinhan Gong; Jian-Min Yuan; Tsung Sheng Wu; Geoffrey L Hammond; Aizhen Jin; Woon-Puay Koh; E L Yong Journal: Bone Date: 2012-03-16 Impact factor: 4.398
Authors: Sherita Hill Golden; Arleen Brown; Jane A Cauley; Marshall H Chin; Tiffany L Gary-Webb; Catherine Kim; Julie Ann Sosa; Anne E Sumner; Blair Anton Journal: J Clin Endocrinol Metab Date: 2012-06-22 Impact factor: 5.958
Authors: Po-Yin Chang; David Feldman; Marcia L Stefanick; Donald P McDonnell; Bonne M Thompson; Jeffrey G McDonald; Jennifer S Lee Journal: J Bone Miner Res Date: 2018-12-07 Impact factor: 6.741
Authors: Meryl S Leboff; Rupali Narweker; Andrea LaCroix; Lieling Wu; Rebecca Jackson; Jennifer Lee; Douglas C Bauer; Jane Cauley; Charles Kooperberg; Cora Lewis; Asha M Thomas; Steven Cummings Journal: J Clin Endocrinol Metab Date: 2009-01-27 Impact factor: 5.958
Authors: D Vanderschueren; S R Pye; K Venken; H Borghs; J Gaytant; I T Huhtaniemi; J E Adams; K A Ward; G Bartfai; F F Casanueva; J D Finn; G Forti; A Giwercman; T S Han; K Kula; F Labrie; M E J Lean; N Pendleton; M Punab; A J Silman; F C W Wu; T W O'Neill; S Boonen Journal: Osteoporos Int Date: 2009-12-15 Impact factor: 4.507
Authors: Carolyn J Crandall; Chi-Hong Tseng; Arun S Karlamangla; Joel S Finkelstein; John F Randolph; Rebecca C Thurston; Mei-Hua Huang; Huiyong Zheng; Gail A Greendale Journal: J Clin Endocrinol Metab Date: 2013-02-26 Impact factor: 5.958